Single-dose psilocybin for a treatment-resistant episode of major depression: Impact on patient-reported depression severity, anxiety, function, and quality of life
Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez, Merve Atli, James C Bennett, Megan Croal, Charles DeBattista, Boadie W Dunlop, David Feifel, David J Hellerstein, Muhammad Ishrat Husain, John R. Kelly, Molly Lennard-Jones, Rasmus W Licht, Lindsey Marwood, Sunil Mistry, Tomáš Páleníček, Ozlem Redjep, Dimitris Repantis, Robert A Schoevers, Batya Septimus, Hollie Simmons, Jair C Soares, Metten Somers, Susan C Stansfield, Jessica R Stuart, Hannah H Tadley, Nisha K Thiara, Joyce Tsai, Mourad Wahba, Sam Williams, Rachel I. Winzer, Allan H. Young, Matthew B Young, Sid Zisook, Ekaterina Malievskaia
Journal of Affective Disorders February 3, 2023 DOI: 10.1016/j.jad.2023.01.108 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Randomized clinical trial Peer reviewed |
|---|---|
| Population | People with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | 25 mg, 10 mg |
| Duration | Three weeks after dosing |
| Topics | Anxiety Depression Psilocybin |
| Keywords | Antidepressant Patient-reported outcomes Psychedelic treatment Hallucinogenic medicine Treatment-resistant depression trd Refractory depression Clinical trials |
| Citations | 168 |
| Key findings | Psilocybin 25 mg and, to a lesser degree, 10 mg improved patient-reported depression severity, anxiety, affect, and functioning three weeks after dosing. |
Abstract
Three weeks after dosing, psilocybin 25 mg and, to a lesser degree, 10 mg improved measures of patient-reported depression severity, anxiety, affect, and functioning. These results extend the primary findings from the largest randomised clinical trial of psilocybin for TRD to examine other outcomes that are of importance to patients.
Comparable studies
Other randomized controlled trials on psilocybin for anxiety, most cited first.